The impact of intravenous fat emulsion administration in acute lung injury

Am J Respir Crit Care Med. 2004 Mar 1;169(5):638-44. doi: 10.1164/rccm.200305-620OC. Epub 2003 Dec 4.

Abstract

The aim of this study was to evaluate the effect of parenteral nutrition containing medium- and long-chain triglycerides on the function of the respiratory system and to investigate mechanisms involved in this process. We studied 13 patients with acute respiratory distress syndrome (ARDS), 8 receiving lipid and 5 placebo, and 6 without ARDS, receiving lipid. Bronchoalveolar lavage (BAL) was performed before and 1 hour after administration of lipid or placebo. In patients with ARDS, lipid administration resulted in deterioration of oxygenation (Pa(O(2))/FI(O(2)): from 129 +/- 37 to 95 +/- 42), compliance of respiratory system (from 39.2 +/- 12 to 33.1 +/- 9.2 ml/cm H(2)O), and pulmonary vascular resistance (from 258 +/- 47 to 321 +/- 58 dyne x s x cm(-5)). In the BAL fluid of the same group, an increase in total protein and phospholipid concentrations, phospholipase activities, platelet-activating factor and neutrophils, as well as alterations in BAL lipid profile were observed. No significant changes were observed in the control or in the ARDS-Placebo groups. In conclusion, this study indicates that administration of medium- and long-chain triglycerides in patients with ARDS causes alterations in lung function and hemodynamics. Inflammatory cells, possibly activated by lipids, release phospholipase A(2) and platelet-activating factor, enhancing edema formation, inflammation, and surfactant alterations.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Blood Gas Analysis
  • Bronchoalveolar Lavage Fluid / chemistry
  • Bronchoalveolar Lavage Fluid / cytology
  • Case-Control Studies
  • Drug Monitoring
  • Fat Emulsions, Intravenous / adverse effects
  • Fat Emulsions, Intravenous / therapeutic use*
  • Female
  • Humans
  • Inflammation
  • Lung Compliance / drug effects
  • Male
  • Middle Aged
  • Neutrophils
  • Phospholipids / analysis
  • Platelet Activating Factor / analysis
  • Proteins / analysis
  • Pulmonary Circulation / drug effects
  • Pulmonary Gas Exchange / drug effects
  • Respiration, Artificial
  • Respiratory Distress Syndrome / etiology
  • Respiratory Distress Syndrome / metabolism
  • Respiratory Distress Syndrome / mortality
  • Respiratory Distress Syndrome / therapy*
  • Survival Analysis
  • Treatment Outcome
  • Vascular Resistance / drug effects

Substances

  • Fat Emulsions, Intravenous
  • Phospholipids
  • Platelet Activating Factor
  • Proteins